ANXA1 and non-small cell lung carcinoma: In addition, in untreated patients (v1) with stage III NSCLC, the differential circulating levels (Figure S1b) of HMGB1, ANXA1, CALR, and CXCL10 were not associated with PFS (Figure 3).